Journal home
Advance online publication
Current issue
Archive
Press releases
Supplements
Focuses
Guide to authors
Online submissionOnline submission
For referees
Free online issue
Contact the journal
Subscribe
Advertising
work@npg
Reprints and permissions
About this site
For librarians
 
NPG Resources
Nature
Nature Reviews
Nature Immunology
Nature Cell Biology
Nature Genetics
news@nature.com
Nature Conferences
Dissect Medicine
NPG Subject areas
Biotechnology
Cancer
Chemistry
Clinical Medicine
Dentistry
Development
Drug Discovery
Earth Sciences
Evolution & Ecology
Genetics
Immunology
Materials Science
Medical Research
Microbiology
Molecular Cell Biology
Neuroscience
Pharmacology
Physics
Browse all publications
Article
Nature Medicine  11, 861 - 866 (2005)
Published online: 10 July 2005; | doi:10.1038/nm1278

Thiazolidinediones expand body fluid volume through PPARbig gamma stimulation of ENaC-mediated renal salt absorption

YouFei Guan1, 2, Chuanming Hao1, 2, Dae Ryong Cha1, 2, Reena Rao1, 2, Wendell Lu1, 2, Donald E Kohan1, 3, 4, Mark A Magnuson2, 5, Reyadh Redha1, 2, Yahua Zhang1, 2 & Matthew D Breyer1, 2, 4, 5

1  Division of Nephrology, Department of Medicine, Vanderbilt University School of Medicine, 21st Avenue South at Garland Avenue, Nashville, Tennessee 37232, USA.

2  S3223 MCN Vanderbilt University School of Medicine, 21st Avenue South at Garland Avenue, Nashville, Tennessee 37232, USA.

3  Department of Nephrology, School of Medicine, University of Utah Medical Center, 50 North Medical Drive, Salt Lake City, Utah 84132-2412, USA.

4  Veterans Affairs Medical Center, 1310 24th Avenue South, Nashville, Tennessee 37212, USA.

5  Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, 21st Avenue South at Garland Avenue, Nashville, Tennessee 37232, USA.

Correspondence should be addressed to Matthew D Breyer matthew.breyer@vanderbilt.edu

Thiazolidinediones (TZDs) are widely used to treat type 2 diabetes mellitus; however, their use is complicated by systemic fluid retention. Along the nephron, the pharmacological target of TZDs, peroxisome proliferator-activated receptor-bold gamma (PPARbold gamma, encoded by Pparg), is most abundant in the collecting duct. Here we show that mice treated with TZDs experience early weight gain from increased total body water. Weight gain was blocked by the collecting duct−specific diuretic amiloride and was also prevented by deletion of Pparg from the collecting duct, using Pparg flox/flox mice. Deletion of collecting duct Pparg decreased renal Na+ avidity and increased plasma aldosterone. Treating cultured collecting ducts with TZDs increased amiloride-sensitive Na+ absorption and Scnn1g mRNA (encoding the epithelial Na+ channel ENaCbold gamma) expression through a PPARbold gamma-dependent pathway. These studies identify Scnn1g as a PPARbold gamma target gene in the collecting duct. Activation of this pathway mediates fluid retention associated with TZDs, and suggests amiloride might provide a specific therapy.

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.

NEWS AND VIEWS

TZDs and diabetes: testing the waters

Nature Medicine News and Views (01 Aug 2005)

 Top
Abstract
Previous | Next
Table of contents
Full textFull text
Download PDFDownload PDF
Send to a friendSend to a friend
Save this linkSave this link

Open Innovation Challenges

naturejobs

Figures & Tables
Supplementary info
See also: News and Views by Semenkovich
Export citation
natureproducts

Search buyers guide:

 
Nature Medicine
ISSN: 1078-8956
EISSN: 1546-170X
Journal home | Advance online publication | Current issue | Archive | Press releases | Supplements | Focuses | For authors | Online submission | For referees | Free online issue | About the journal | Contact the journal | Subscribe | Advertising | work@npg | Reprints and permissions | About this site | For librarians
Nature Publishing Group, publisher of Nature, and other science journals and reference works©2005 Nature Publishing Group | Privacy policy